XLON
HEMO
Market cap10mUSD
, Last price
GBX
Name
Hemogenyx Pharmaceuticals PLC
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
25.68%
Rev. gr., 5y
%
Revenues
0k
Net income
-7m
L+53.87%
CFO
-6m
L+109.77%
Earnings
Sep 25, 2025
Profile
Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML), subset of acute lymphoblastic leukaemia, and myelodysplastic syndrome conditioning bone marrow transplants to substitute traditional chemotherapy and/or radiation; HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants. The company was founded in 2012 and is headquartered in London, the United Kingdom.
Valuation
Title GBP in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | 5,649 | 3,542 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (5,649) | (3,542) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | 361 | ||||||||
Tax Rate | |||||||||
NOPAT | (5,649) | (3,903) | |||||||
Net income | (6,691) 53.87% | (4,348) -42.20% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 5,088 | ||||||||
BB yield | -19.59% | ||||||||
| Debt | |||||||||
Debt current | 273 | 322 | |||||||
Long-term debt | 5,619 | 6,524 | |||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | 4,644 | 4,313 | |||||||
| Cash flow | |||||||||
Cash from operating activities | (6,106) | (2,911) | |||||||
CAPEX | (117) | (429) | |||||||
Cash from investing activities | (420) | ||||||||
Cash from financing activities | 4,449 | (110) | |||||||
FCF | (5,666) | (7,022) | |||||||
| Balance | |||||||||
Cash | 1,248 | 2,533 | |||||||
Long term investments | |||||||||
Excess cash | 1,248 | 2,533 | |||||||
Stockholders' equity | (12,087) | (7,348) | |||||||
Invested Capital | 17,891 | 14,015 | |||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 1,129,137 | 979,749 | |||||||
Price | 0.02 73.58% | 0.01 -29.33% | |||||||
Market cap | 25,970 100.05% | 12,982 -10.54% | |||||||
EV | 30,577 | 17,321 | |||||||
EBITDA | (5,003) | (3,347) | |||||||
EV/EBITDA | |||||||||
Interest | 316 | 33 | |||||||
Interest/NOPBT | |||||||||